AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KJUL 12 min read$CLYM

Climb Bio, Inc. (CLYM): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Climb Bio, Inc. (CLYM) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001768446 0001768446 2026-06-29 2026-06-29 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29,

Original reporting
SEC EDGAR 8-K
Published Jul 1, 2026, 8:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 1, 2026, 8:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefCorporate actions
Primary signal
$CLYM
Neutral
medium confidence
Mentioned
$CLYM
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$CLYMNeutralLow
01

Why it matters

The only new, decision-relevant details are the resignation of Andrew Levin and the immediate election of Breanna O’Reilly, plus her director compensation structure and option grant terms.

02

Market read

Updates CLYM’s board composition and director compensation; no clinical, regulatory, or financial guidance is provided.

03

What to watch

Traders may overreact to the option strike ($13.36) despite it being set to the closing price on the grant date, not a forward-looking valuation signal.

Relevance 6/10Novelty 5/10Timing: filed July 1, 2026 (after-hours/late day) following June 29 board actions

Background

This is an SEC Form 8-K (Item 5.02) reporting director/officer changes and compensatory arrangements.

Company-level read

Ticker impact

$CLYMNeutralMedium confidence
Context

Climb Bio disclosed a director resignation and the immediate election of Breanna O’Reilly, including a 70,284-share option grant at $13.36.

Expected impact

Low probability of a sustained move; any reaction likely limited to governance/compensation sentiment.

Evidence & confidence

The filing is a routine 8-K (Item 5.02) with no operational or financial guidance, but it is a fresh, company-specific datapoint (new director + option terms).

Market effects

Sector

Minimal; governance/compensation changes at a single biotech typically do not reset sector risk premia.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The director change could be interpreted as internal reshuffling ahead of upcoming catalysts, but the filing provides no explicit link to strategy or trials.

Key entities

  • company
    Climb Bio, Inc.

    Nasdaq-listed biotech issuer filing the 8-K reporting board changes and director compensation.

  • person
    Andrew Levin

    Resigned as a director effective immediately on June 29, 2026.

  • person
    Breanna O’Reilly, Ph.D.

    Elected as a director effective immediately on June 29, 2026; receives director compensation and an option grant.

Read at source← All news

Related articles

OCT 24
$CLYMHighAI 8/10

Climb Bio reports early data on budoprutug for kidney diseases

Climb Bio (CLYM) presented Phase 2 trial data for budoprutug, an anti-CD19 antibody, showing B-cell depletion and PLA2R antibody reductions in kidney disease patients. The 200 mg dose achieved 70% mean antibody reduction, with 5/13 patients in remission. The 600 mg dose showed deeper B-cell depletion. The drug was well-tolerated. Climb Bio expects more data in 2027. Primary membranous nephropathy affects 75,000 people in the U.S. without FDA-approved treatments.

investing.com2 min
OCT 24
$CLYMMedAI 8/10

Climb Bio’s Anti-APRIL Antibody Shows ~70% Gd-IgA1 Reduction at 12 Weeks

Climb Bio (CLYM) and Beijing Mabworks reported Phase 1 data showing their anti-APRIL antibody reduced Gd-IgA1 by ~70% and IgA by ~60% at 12 weeks in healthy volunteers. The trials involved 88 participants across Australia and China. The antibody was well-tolerated, with no serious adverse events. The company plans to initiate a Phase 3 trial in 2027, pending regulatory feedback.

minichart.com.sg2 min
OCT 23
$CLYMMedAI 8/10

Climb Bio Reports CLYM116 Phase 1 Data Supporting 12-Week Dosing

Climb Bio reported Phase 1 results for CLYM116, showing sustained APRIL suppression through 12 weeks and reductions in IgA and Gd-IgA1. A single dose of at least 480 mg suppressed free APRIL by 90% or more, supporting a potential every-12-week regimen. The antibody was generally well tolerated. Phase 2 trial is enrolling, with initial data expected in the first half of 2027, and a Phase 3 trial is expected to begin in 2027, pending regulatory feedback.

tradingview.com1 min
OCT 23
$CLYMHighAI 8/10

Climb Bio and Mabworks Announce CLYM116/MIL116 Data Demonstrating Deep, Durable APRIL Suppression and ~70% Gd-IgA1 Reduction at ASN Kidney Week 2026

Climb Bio, Inc. (CLYM) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Climb Bio and Mabworks Announce CLYM116/MIL116 Data Demonstrating Deep, Durable APRIL Suppression and ~70% Gd-IgA1 Reduction at ASN Kidney Week 2026 >90% free APRIL suppression sustained through 12 weeks, supporting Q12W dosing interval ~70% reduction in Gd-IgA1 at 1

SEC EDGAR 8-K2 min